Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wirral University Teaching Hospital NHS Trust
• Collaborator: AstraZeneca
• Treatments: Bicalutamide

Criteria

Inclusion Criteria:

• Osteoporotic patients (T score ≤ -2.5) with advanced prostate cancer requiring hormone manipulation, due to biochemical relapse following either radical prostatectomy, radiotherapy, brachytherapy, or biochemical progression after initially being observed with prostate cancer.

Exclusion Criteria:

• Severe hepatic insufficiency, with bilirubin above reference range

• Previous systemic therapy for prostate cancer

• Radiotherapy within 6 months

• Previous other invasive malignancies

• Any severe concomitant disease.